Show simple item record

dc.creatorSpasić, Snežana
dc.creatorNikolić-Kokić, Aleksandra
dc.creatorMiletić, Srđan
dc.creatorOreščanin-Dušić, Zorana
dc.creatorSpasić, Mihajlo
dc.creatorBlagojević, Duško
dc.creatorStević, Zorica
dc.date.accessioned2020-12-03T19:53:30Z
dc.date.available2020-12-01
dc.date.issued2020
dc.identifier.issn1389-4501
dc.identifier.urihttps://www.eurekaselect.com/179582/article
dc.identifier.urihttps://cer.ihtm.bg.ac.rs/handle/123456789/3966
dc.description.abstractRadicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.en
dc.language.isoensr
dc.publisherBentham Sciencesr
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173014/RS//sr
dc.rightsembargoedAccesssr
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceCurrent Drug Targetssr
dc.subjectEdaravonesr
dc.subjectamyotrophic lateral sclerosis (ALS)sr
dc.subjectferroptosissr
dc.subjecttherapysr
dc.subjectneuronssr
dc.subjectneurodegenerationsr
dc.titleEdaravone May Prevent Ferroptosis in ALSen
dc.typearticlesr
dc.rights.licenseBY-NC-NDsr
dcterms.abstractСтевић, Зорица; Милетић, Срђан; Спасић, Снежана; Николић-Кокић, Aлександра; Благојевић, Душко; Спасић, Михајло; Орешчанин-Душић, Зорана;
dc.citation.volume21
dc.citation.issue8
dc.citation.spage776
dc.citation.epage780
dc.citation.rankM22~
dc.description.otherThis is the peer-reviewed version of the article: Spasic, Snezana; Nikolic-Kokic, Aleksandra; Miletic, Srdan; Orescanin-Dusic, Zorana; Spasic, Mihajlo B; Blagojevic, Dusko; Stevic, Zorica. Curr Drug Targets ; 21(8): 776-780, 2020, doi: [https://doi.org/10.2174/1389450121666200220123305]en
dc.identifier.doi10.2174/1389450121666200220123305
dc.identifier.fulltexthttp://cer.ihtm.bg.ac.rs/bitstream/id/18292/2020_edaravon_sspasic.pdf
dc.identifier.scopus2-s2.0-85087096289
dc.identifier.wos000542986600002
dc.type.versionacceptedVersionsr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record